cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2023-38-2-51-56cardiotomsk-1786Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESРоль эритропоэтина в регуляции толерантности сердца к действию ишемии и реперфузииThe role of erythropoietin in the regulation of cardiac tolerance to impact of ischemia and reperfusionhttps://orcid.org/0000-0003-1291-0661СуфиановаГ. З.SufianovaG. Z.

Суфианова Галина Зиновьевна д-р мед. наук,  профессор, заведующий кафедрой фармакологии 

 625023, Российская Федерация, Тюмень, ул. Одесская, 54 

Galina Z. Sufianova - Dr. Sci. (Med.), Head of the Department of Pharmacology

 54, Odesskaya str., Tyumen, 625023, Russian Federation 

sufarm@mail.ruhttps://orcid.org/0000-0001-6216-0825ШапкинА. Г.ShapkinA. G.

Шапкин Андрей Григорьевич - канд. мед. наук, доцент кафедры фармакологии

625023, Российская Федерация, Тюмень, ул. Одесская, 54 

Andrei G. Shapkin - Cand. Sci. (Med.), Associate Professor, Department of Pharmacology 

 54, Odesskaya str., Tyumen, 625023, Russian Federation 

a.g.shapkin@gmail.comhttps://orcid.org/0000-0002-5966-8916ХлёсткинаМ. С.KhlestkinaM. S.

Хлёсткина Мария Сергеевна - канд. мед. наук, доцент кафедры фармакологии

 625023, Российская Федерация, Тюмень, ул. Одесская, 54 

Maria S. Khlestkina - Cand. Sci. (Med.), Associate Professor, Department of Pharmacology 

 54, Odesskaya str., Tyumen, 625023, Russian Federation 

kh_m_s@mail.ruhttps://orcid.org/0000-0003-1808-556XМухомедзяновА. В.MukhomedzyanovA. V.

Мухомедзянов Александр Валерьевич - младший научный сотрудник, лаборатория экспериментальной кардиологии

 634012, Российская Федерация, Томск, ул. Киевская, 111а 

Aleksandr V. Mukhomedzyanov - Cand. Sci. (Med.) 

111а, Kievskaya str., Tomsk, 634012, Russian Federation 

 

sasha_m91@mail.ruhttps://orcid.org/0000-0002-5890-071XГорбуновА. С.GorbunovA. S.

Горбунов Александр Сергеевич - канд. мед. наук, старший научный сотрудник, лаборатория экспериментальной кардиологии

 634012, Российская Федерация, Томск, ул. Киевская, 111а 

Aleksandr S. Gorbunov - Cand. Sci. (Med.), Senior Research Scientist, Laboratory of Experimental Cardiology 

 111а, Kievskaya str., Tomsk, 634012, Russian Federation 

barabator@sibmail.comhttps://orcid.org/0000-0002-6020-1598МасловЛ. Н.MaslovL. N.

Маслов Леонид Николаевич - д-р мед. наук, профессор, заведующий лабораторией экспериментальной кардиологии 

634012, Российская Федерация, Томск, ул. Киевская, 111а 

Leonid N. Maslov - Dr. Sci. (Med.), Professor, Head of Laboratory of Experimental Cardiology 

 111а, Kievskaya str., Tomsk, 634012, Russian Federation 

Maslov@cardio.tomsk.ruТюменский государственный медицинский университет Министерства здравоохранения Российской ФедерацииРоссияTyumen State Medical University of the Russian FederationRussian FederationНаучно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian Federation2023040720233825156Copyright © Суфианова Г.З., Шапкин А.Г., Хлёсткина М.С., Мухомедзянов А.В., Горбунов А.С., Маслов Л.Н., 20232023Суфианова Г.З., Шапкин А.Г., Хлёсткина М.С., Мухомедзянов А.В., Горбунов А.С., Маслов Л.Н.Sufianova G.Z., Shapkin A.G., Khlestkina M.S., Mukhomedzyanov A.V., Gorbunov A.S., Maslov L.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/1786

Острый инфаркт миокарда (ОИМ) является одной из главных причин смертности трудоспособного населения в России и населения экономически развитых стран. В последние годы смертность от ОИМ в США и Европе не снижается. Связано это с отсутствием высокоэффективных лекарственных средств для терапии ОИМ. Одним из перспективных препаратов для повышения выживаемости пациентов с ОИМ является эритропоэтин. Нами проведен поиск полнотекстовых публикаций в базе данных PubMed и на сайте журнала Nature. В исследованиях, выполненных на животных, было показано, что эритропоэтин (5000 Ед/кг) способен повысить толерантность сердца к ишемии и реперфузии за счет активации ряда киназ (ПКС, ERK1/2, Akt, JAK2, PI3K) и за счет инактивации киназы GSK-3β. Эритропоэтин препятствует постинфарктному ремоделированию сердца и усиливает процесс неоваскуляризации миокарда у крыс и собак. Эритропоэтин в используемых дозировках (в среднем около 1000 Ед/кг) не влияет на размер инфаркта у пациентов с ОИМ и не оказывает эффекта на постинфарктное ремоделирование сердца у человека. Причина подобного расхождения экспериментальных и клинических данных остается неясной. Возможно, что применение больших доз эритропоэтина или использование его аналогов, не влияющих на эритропоэз, сможет предупредить развитие постинфарктного ремоделирования сердца у человека.

Acute myocardial infarction (AMI) is one of the main causes of mortality among the able-bodied population in Russia and the population of economically developed countries. In recent years, deaths from AMI in the USA and Europe have not decreased. This is due to the lack of highly effective drugs for the treatment of AMI. One of the promising drugs to improve the survival of patients with AMI is erythropoietin. We searched for full-text publications in the PubMed database and on the website of the journal Nature. In studies performed on animals, it was shown that erythropoietin (5000 U/kg) is able to increase cardiac tolerance to ischemia and reperfusion due to activation of a number of kinases (PKC, ERK1/2, Akt, JAK2, PI3K) and due to GSK-3β kinase inactivation. Erythropoietin prevents post-infarction remodeling of the heart and enhances the process of myocardial neovascularization in rats and dogs. Erythropoietin in used doses (on the average 1000 U/kg) does not affect infarct size in patients with AMI and does not have an effect on post-infarction ventricular remodeling in humans. The reason for this discrepancy between experimental and clinical data remains unclear. It is possible that the use of large doses of erythropoietin or the use of its analogues that do not affect erythropoiesis can prevent the development of post-infarction cardiac remodeling in humans.

сердцеишемияреперфузияэритропоэтинheartischemiareperfusionerythropoietinСтатья подготовлена при поддержке гранта РФФИ 18-415-700004. Раздел, посвященный роли киназ в кардиопротекторных эффектах эритропоэтина, оформлен в рамках гос. задания АААА-А15-115120910024-0.this article was prepared with the support of a grant from the Russian Foundation of Basic Research 18-415-700004. The section on a role of kinases in the cardioprotective effects of erythropoietin is prepared within the framework of the state tasks AAAA-A15-115120910024-0.ReferencesMenees D.S., Peterson E.D., Wang Y., Curtis J.P., Messenger J.C., Rumsfeld J.S. et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N. Engl. J. Med. 2013;369(10):901–909. DOI: 10.1056/NEJMoa1208200.Menees D.S., Peterson E.D., Wang Y., Curtis J.P., Messenger J.C., Rumsfeld J.S. et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N. Engl. J. Med. 2013;369(10):901–909. DOI: 10.1056/NEJMoa1208200.Zhou Y., Chen S., Zhu X., Gui J., Abusaada K. Prior beta blockers use is independently associated with increased inpatient mortality in patients presenting with acute myocardial infarction. Int. J. Cardiol. 2017;243:81–85. DOI: 10.1016/j.ijcard.2017.03.004.Zhou Y., Chen S., Zhu X., Gui J., Abusaada K. Prior beta blockers use is independently associated with increased inpatient mortality in patients presenting with acute myocardial infarction. Int. J. Cardiol. 2017;243:81–85. DOI: 10.1016/j.ijcard.2017.03.004.Vaidya S.R., Devarapally S.R., Arora S. Infarct related artery only versus complete revascularization in ST-segment elevation myocardial infarction and multi vessel disease: a meta-analysis. Cardiovasc. Diagn. Ther. 2017;7(1):16–26. DOI: 10.21037/cdt.2016.08.06.Vaidya S.R., Devarapally S.R., Arora S. Infarct related artery only versus complete revascularization in ST-segment elevation myocardial infarction and multi vessel disease: a meta-analysis. Cardiovasc. Diagn. Ther. 2017;7(1):16–26. DOI: 10.21037/cdt.2016.08.06.Bunn H.F. Erythropoietin. Cold. Spring. Harb. Perspect. Med. 2013;3(3):a011619. DOI: 10.1101/cshperspect.a011619.Bunn H.F. Erythropoietin. Cold. Spring. Harb. Perspect. Med. 2013;3(3):a011619. DOI: 10.1101/cshperspect.a011619.Carnot P., Deflandre C. Sur l’activite hemopoietique des differents organeau au cours de la regeneration du sang. CR Searces. Acad. Sci. 1906;143:432–435.Carnot P., Deflandre C. Sur l’activite hemopoietique des differents organeau au cours de la regeneration du sang. CR Searces. Acad. Sci. 1906;143:432–435.Krumdieck N. Erythropoietic substance in the serum of anemic animals. Exp. Biol. Med. 1943;54(1):14–17. DOI: 10.3181/00379727-54-14283.Krumdieck N. Erythropoietic substance in the serum of anemic animals. Exp. Biol. Med. 1943;54(1):14–17. DOI: 10.3181/00379727-54-14283.Jacobson L.O., Marks E., Gaston E., Goldwasser E. Role of the kidney in erythropoiesis. Nature. 1957;179(4560):633–634. DOI: 10.1038/179633a0.Jacobson L.O., Marks E., Gaston E., Goldwasser E. Role of the kidney in erythropoiesis. Nature. 1957;179(4560):633–634. DOI: 10.1038/179633a0.Baker J.E. Erythropoietin mimics ischemic preconditioning. Vascul. Pharmacol. 2005;42(5–6):233–241. DOI: 10.1016/j.vph.2005.02.004.Baker J.E. Erythropoietin mimics ischemic preconditioning. Vascul. Pharmacol. 2005;42(5–6):233–241. DOI: 10.1016/j.vph.2005.02.004.Calvillo L., Latini R., Kajstura J., Leri A., Anversa P., Ghezzi P. et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci. 2003;100(8):4802–4806. DOI: 10.1073/pnas.0630444100.Calvillo L., Latini R., Kajstura J., Leri A., Anversa P., Ghezzi P. et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci. 2003;100(8):4802–4806. DOI: 10.1073/pnas.0630444100.Beleslin-Cokic B.B., Cokic V.P., Yu X., Weksler B.B., Schechter A.N., Noguchi C.T. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood. 2004;104(7):2073–2080. DOI: 10.1182/blood-2004-02-0744.Beleslin-Cokic B.B., Cokic V.P., Yu X., Weksler B.B., Schechter A.N., Noguchi C.T. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood. 2004;104(7):2073–2080. DOI: 10.1182/blood-2004-02-0744.Miyake T., Kung C.K.H., Goldwasser E. Purification of human erythropoietin. J. Biol. Chem. 1977;252(15):5558–5564.Miyake T., Kung C.K.H., Goldwasser E. Purification of human erythropoietin. J. Biol. Chem. 1977;252(15):5558–5564.Jacobs K., Shoemaker C., Rudersdorf R., Neill S.D., Kaufman R.J., Mufson A. et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313(6005):806–810. DOI: 10.1038/313806a0.Jacobs K., Shoemaker C., Rudersdorf R., Neill S.D., Kaufman R.J., Mufson A. et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313(6005):806–810. DOI: 10.1038/313806a0.Collino M., Thiemermann C., Cerami A., Brines M. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol. Ther. 2015;151:32–40. DOI: 10.1016/j.pharmthera.2015.02.005.Collino M., Thiemermann C., Cerami A., Brines M. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol. Ther. 2015;151:32–40. DOI: 10.1016/j.pharmthera.2015.02.005.Ridley D.M., Dawkins F., Perlin E. Erythropoietin: a review. J. Natl. Med. Assoc. 1994;86(2):129–135.Ridley D.M., Dawkins F., Perlin E. Erythropoietin: a review. J. Natl. Med. Assoc. 1994;86(2):129–135.Held M.A., Greenfest-Allen E., Su S., Stoeckert C.J., Stokes M.P., Wojchowski D.M. Phospho-PTM proteomic discovery of novel EPO-modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 signaling. Cell. Signal. 2020;69:109554. DOI: 10.1016/j.cellsig.2020.109554.Held M.A., Greenfest-Allen E., Su S., Stoeckert C.J., Stokes M.P., Wojchowski D.M. Phospho-PTM proteomic discovery of novel EPO-modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 signaling. Cell. Signal. 2020;69:109554. DOI: 10.1016/j.cellsig.2020.109554.Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ. Res. 2015;116(4):674–699. DOI: 10.1161/CIRCRESAHA.116.305348.Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ. Res. 2015;116(4):674–699. DOI: 10.1161/CIRCRESAHA.116.305348.Yamaji R., Okada T., Moriya M., Naito M., Tsuruo T., Miyatake K. et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur. J. Biochem. 1996;239(2):494–500. DOI: 10.1111/j.1432-1033.1996.0494u.x.Yamaji R., Okada T., Moriya M., Naito M., Tsuruo T., Miyatake K. et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur. J. Biochem. 1996;239(2):494–500. DOI: 10.1111/j.1432-1033.1996.0494u.x.van der Meer P., Lipsic E., Henning R.H., de Boer R.A., Suurmeijer A.J., van Veldhuisen D.J. et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur. J. Heart. Fail. 2004;6(7):853–859. DOI: 10.1016/j.ejheart.2004.03.012.van der Meer P., Lipsic E., Henning R.H., de Boer R.A., Suurmeijer A.J., van Veldhuisen D.J. et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur. J. Heart. Fail. 2004;6(7):853–859. DOI: 10.1016/j.ejheart.2004.03.012.Zafeiriou M.P. The Erythropoietin system protects the heart upon injury by cardiac progenitor cell activation. Vitam. Horm. 2017;105:233–248. DOI: 10.1016/bs.vh.2017.04.001.Zafeiriou M.P. The Erythropoietin system protects the heart upon injury by cardiac progenitor cell activation. Vitam. Horm. 2017;105:233–248. DOI: 10.1016/bs.vh.2017.04.001.Brines M., Cerami A. Discovering erythropoietin’s extra-hematopoietic functions: biology and clinical promise. Kidney Int. 2006;70(2):246–250. DOI: 10.1038/sj.ki.5001546.Brines M., Cerami A. Discovering erythropoietin’s extra-hematopoietic functions: biology and clinical promise. Kidney Int. 2006;70(2):246–250. DOI: 10.1038/sj.ki.5001546.van der Kooij M.A., Groenendaal F., Kavelaars A., Heijnen C.J., van Bel F. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res. Rev. 2008;59(1):22–33. DOI: 10.1016/j.brainresrev.2008.04.007.van der Kooij M.A., Groenendaal F., Kavelaars A., Heijnen C.J., van Bel F. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res. Rev. 2008;59(1):22–33. DOI: 10.1016/j.brainresrev.2008.04.007.Schödel J., Ratcliffe P.J. Mechanisms of hypoxia signalling: new implications for nephrology. Nat. Rev. Nephrol. 2019;15(10):641–659. DOI: 10.1038/s41581-019-0182-z.Schödel J., Ratcliffe P.J. Mechanisms of hypoxia signalling: new implications for nephrology. Nat. Rev. Nephrol. 2019;15(10):641–659. DOI: 10.1038/s41581-019-0182-z.Villa P., Bigini P., Mennini T., Agnello D., Laragione T., Cagnotto A. et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J. Exp. Med. 2003;198(6):971–975. DOI: 10.1084/jem.20021067.Villa P., Bigini P., Mennini T., Agnello D., Laragione T., Cagnotto A. et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J. Exp. Med. 2003;198(6):971–975. DOI: 10.1084/jem.20021067.Kittur F.S., Lin Y., Arthur E., Hung C.Y., Li P.A., Sane D.C. et al. Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation. Biochem. Biophys. Rep. 2019;17:157–168. DOI: 10.1016/j.bbrep.2019.01.004.Kittur F.S., Lin Y., Arthur E., Hung C.Y., Li P.A., Sane D.C. et al. Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation. Biochem. Biophys. Rep. 2019;17:157–168. DOI: 10.1016/j.bbrep.2019.01.004.Li R., Zhang L.M., Sun W.B. Erythropoietin rescues primary rat cortical neurons from pyroptosis and apoptosis via Erk1/2-Nrf2/Bach1 signal pathway. Brain Res. Bull. 2017;130:236–244. DOI: 10.1016/j.brainresbull.2017.01.016.Li R., Zhang L.M., Sun W.B. Erythropoietin rescues primary rat cortical neurons from pyroptosis and apoptosis via Erk1/2-Nrf2/Bach1 signal pathway. Brain Res. Bull. 2017;130:236–244. DOI: 10.1016/j.brainresbull.2017.01.016.Cohen M.V., Downey J.M. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br. J. Pharmacol. 2015;172(8):1913–1932. DOI: 10.1111/bph.12903.Cohen M.V., Downey J.M. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br. J. Pharmacol. 2015;172(8):1913–1932. DOI: 10.1111/bph.12903.Bullard A.J., Govewalla P., Yellon D.M. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic. Res. Cardiol. 2005;100(5):397–403. DOI: 10.1007/s00395-005-0537-4.Bullard A.J., Govewalla P., Yellon D.M. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic. Res. Cardiol. 2005;100(5):397–403. DOI: 10.1007/s00395-005-0537-4.Garg K., Sharma P., Yadav H., Singh M. Mechanism of cardioprotective effect of erythropoietin-induced preconditioning in rat heart. Indian J. Pharmacol. 2010;42(4):219. DOI: 10.4103/0253-7613.68421.Garg K., Sharma P., Yadav H., Singh M. Mechanism of cardioprotective effect of erythropoietin-induced preconditioning in rat heart. Indian J. Pharmacol. 2010;42(4):219. DOI: 10.4103/0253-7613.68421.Tsibulnikov S.Y., Maslov L.N., Gorbunov A.S., Voronkov N.S., Boshchenko A.A., Popov S.V. et al. A Review of humoral factors in remote preconditioning of the heart. J. Cardiovasc. Pharmacol. Ther. 2019;24(5):403–421. DOI: 10.1177/1074248419841632.Tsibulnikov S.Y., Maslov L.N., Gorbunov A.S., Voronkov N.S., Boshchenko A.A., Popov S.V. et al. A Review of humoral factors in remote preconditioning of the heart. J. Cardiovasc. Pharmacol. Ther. 2019;24(5):403–421. DOI: 10.1177/1074248419841632.Suarez-Mendez S., Tovilla-Zárate C.A., Juárez-Rojop I.E., Bermú-dez-Ocaña D.Y. Erythropoietin: A potential drug in the management of diabetic neuropathy. Biomed. Pharmacother. 2018;105:956–961. DOI: 10.1016/j.biopha.2018.06.068.Suarez-Mendez S., Tovilla-Zárate C.A., Juárez-Rojop I.E., Bermú-dez-Ocaña D.Y. Erythropoietin: A potential drug in the management of diabetic neuropathy. Biomed. Pharmacother. 2018;105:956–961. DOI: 10.1016/j.biopha.2018.06.068.Ghaboura N., Tamareille S., Ducluzeau P.-H., Grimaud L., Loufrani L., Croué A. et al. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling. Basic. Res. Cardiol. 2011;106(1):147–162. DOI: 10.1007/s00395-010-0130-3.Ghaboura N., Tamareille S., Ducluzeau P.-H., Grimaud L., Loufrani L., Croué A. et al. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling. Basic. Res. Cardiol. 2011;106(1):147–162. DOI: 10.1007/s00395-010-0130-3.Tan R., Tian H., Yang B., Zhang B., Dai C., Han Z. et al. Autophagy and Akt in the protective effect of erythropoietin helix B surface peptide against hepatic ischaemia/reperfusion injury in mice. Sci. Rep. 2018;8(1):14703. DOI: 10.1038/s41598-018-33028-3.Tan R., Tian H., Yang B., Zhang B., Dai C., Han Z. et al. Autophagy and Akt in the protective effect of erythropoietin helix B surface peptide against hepatic ischaemia/reperfusion injury in mice. Sci. Rep. 2018;8(1):14703. DOI: 10.1038/s41598-018-33028-3.Yu J., Shi Z., Su X., Zhou Y., Li B., Wang S. et al. Expression of Bcl-2 and Bad in hippocampus of status epileptic rats and molecular mechanism of intervened recombinant human erythropoietin. Exp. Ther. Med. 2018;16(2):847–855. DOI: 10.3892/etm.2018.6250.Yu J., Shi Z., Su X., Zhou Y., Li B., Wang S. et al. Expression of Bcl-2 and Bad in hippocampus of status epileptic rats and molecular mechanism of intervened recombinant human erythropoietin. Exp. Ther. Med. 2018;16(2):847–855. DOI: 10.3892/etm.2018.6250.Xie Y., Shi X., Sheng K., Han G., Li W., Zhao Q. et al. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). Mol. Med. Rep. 2019;19(2):783–791. DOI: 10.3892/mmr.2018.9713.Xie Y., Shi X., Sheng K., Han G., Li W., Zhao Q. et al. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). Mol. Med. Rep. 2019;19(2):783–791. DOI: 10.3892/mmr.2018.9713.Si W., Wang J., Li M., Qu H., Gu R., Liu R. et al. Erythropoietin protects neurons from apoptosis via activating PI3K/AKT and inhibiting Erk1/2 signaling pathway. 3 Biotech. 2019;9(4):131. DOI: 10.1007/s13205-019-1667-y.Si W., Wang J., Li M., Qu H., Gu R., Liu R. et al. Erythropoietin protects neurons from apoptosis via activating PI3K/AKT and inhibiting Erk1/2 signaling pathway. 3 Biotech. 2019;9(4):131. DOI: 10.1007/s13205-019-1667-y.Kreisman N.R., Wooliscroft L.B., Campbell C.F., Dotiwala A.K., Cox M.L., Denson A.C. et al. Preconditioning hippocampal slices with hypothermia promotes rapid tolerance to hypoxic depolarization and swelling: Mediation by erythropoietin. Brain Res. 2020;1726:146517. DOI: 10.1016/j.brainres.2019.146517.Kreisman N.R., Wooliscroft L.B., Campbell C.F., Dotiwala A.K., Cox M.L., Denson A.C. et al. Preconditioning hippocampal slices with hypothermia promotes rapid tolerance to hypoxic depolarization and swelling: Mediation by erythropoietin. Brain Res. 2020;1726:146517. DOI: 10.1016/j.brainres.2019.146517.Liu F., Wen Y., Kang J., Wei C., Wang M., Zheng Z. et al. Regulation of TLR4 expression mediates the attenuating effect of erythropoietin on inflammation and myocardial fibrosis in rat heart. Int. J. Mol. Med. 2018;42(3):1436–1444. DOI: 10.3892/ijmm.2018.3707.Liu F., Wen Y., Kang J., Wei C., Wang M., Zheng Z. et al. Regulation of TLR4 expression mediates the attenuating effect of erythropoietin on inflammation and myocardial fibrosis in rat heart. Int. J. Mol. Med. 2018;42(3):1436–1444. DOI: 10.3892/ijmm.2018.3707.Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B. et al. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 2003;112(7):999–1007. DOI: 10.1172/JCI18200.Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B. et al. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 2003;112(7):999–1007. DOI: 10.1172/JCI18200.Lipsic E., van der Meer P., Henning R.H., Suurmeijer A.J., Boddeus K.M., van Veldhuisen D.J. et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharmacol. 2004;44(4):473–479. DOI: 10.1097/01.fjc.0000140209.04675.c3.Lipsic E., van der Meer P., Henning R.H., Suurmeijer A.J., Boddeus K.M., van Veldhuisen D.J. et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharmacol. 2004;44(4):473–479. DOI: 10.1097/01.fjc.0000140209.04675.c3.Moon C., Krawczyk M., Ahn D., Ahmet I., Paik D., Lakatta E.G. et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl. Acad. Sci. USA. 2003;100(20):11612–11617. DOI: 10.1073/pnas.1930406100.Moon C., Krawczyk M., Ahn D., Ahmet I., Paik D., Lakatta E.G. et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl. Acad. Sci. USA. 2003;100(20):11612–11617. DOI: 10.1073/pnas.1930406100.Hale S.L., Sesti C., Kloner R.A. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J. Cardiovasc. Pharmacol. 2005;46(2):211–215. DOI: 10.1097/01.fjc.0000171751.05446.c5.Hale S.L., Sesti C., Kloner R.A. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J. Cardiovasc. Pharmacol. 2005;46(2):211–215. DOI: 10.1097/01.fjc.0000171751.05446.c5.Prunier F., Pfister O., Hadri L., Liang L., Del Monte F., Liao R. et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am. J. Physiol. Circ. Physiol. 2007;292(1):H522–H529. DOI: 10.1152/ajpheart.00357.2006.Prunier F., Pfister O., Hadri L., Liang L., Del Monte F., Liao R. et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am. J. Physiol. Circ. Physiol. 2007;292(1):H522–H529. DOI: 10.1152/ajpheart.00357.2006.van der Meer P., Lipsic E., Henning R.H., Boddeus K., van der Velden J., Voors A.A. et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J. Am. Coll. Cardiol. 2005;46(1):125–133. DOI: 10.1016/j.jacc.2005.03.044.van der Meer P., Lipsic E., Henning R.H., Boddeus K., van der Velden J., Voors A.A. et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J. Am. Coll. Cardiol. 2005;46(1):125–133. DOI: 10.1016/j.jacc.2005.03.044.Hirata A., Minamino T., Asanuma H., Fujita M., Wakeno M., Myoishi M. et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J. Am. Coll. Cardiol. 2006;48(1):176–184. DOI: 10.1016/j.jacc.2006.04.008.Hirata A., Minamino T., Asanuma H., Fujita M., Wakeno M., Myoishi M. et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J. Am. Coll. Cardiol. 2006;48(1):176–184. DOI: 10.1016/j.jacc.2006.04.008.Ott I., Schulz S., Mehilli J., Fichtner S., Hadamitzky M., Hoppe K. et al. Erythropoietin in patients with acute ST-Segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circ. Cardiovasc. Interv. 2010;3(5):408–413. DOI: 10.1161/CIRCINTERVENTIONS.109.904425.Ott I., Schulz S., Mehilli J., Fichtner S., Hadamitzky M., Hoppe K. et al. Erythropoietin in patients with acute ST-Segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circ. Cardiovasc. Interv. 2010;3(5):408–413. DOI: 10.1161/CIRCINTERVENTIONS.109.904425.Voors A.A., Belonje A.M.S., Zijlstra F., Hillege H.L., Anker S.D., Slart R.H. et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur. Heart J. 2010;31(21):2593–2600. DOI:10.1093/eurheartj/ehq304.Voors A.A., Belonje A.M.S., Zijlstra F., Hillege H.L., Anker S.D., Slart R.H. et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur. Heart J. 2010;31(21):2593–2600. DOI:10.1093/eurheartj/ehq304.Najjar S.S., Rao S.V., Melloni C., Raman S.V., Povsic T.J., Melton L. et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA. 2011;305(18):1863–1872. DOI: 10.1001/jama.2011.592.Najjar S.S., Rao S.V., Melloni C., Raman S.V., Povsic T.J., Melton L. et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA. 2011;305(18):1863–1872. DOI: 10.1001/jama.2011.592.Prunier F., Bière L., Gilard M., Boschat J., Mouquet F., Bauchart J.J. et al. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am. Heart J. 2012;163(2):200–207. DOI: 10.1016/j.ahj.2011.11.005.Prunier F., Bière L., Gilard M., Boschat J., Mouquet F., Bauchart J.J. et al. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am. Heart J. 2012;163(2):200–207. DOI: 10.1016/j.ahj.2011.11.005.Gholamzadeh A., Amini S., Mohammadpour A.H., Vahabzadeh M., Fazelifar A.F., Fazlinezhad A. et al. Erythropoietin reduces PostPCI arrhythmias in patients with ST-elevation myocardial infarction. J. Cardiovasc. Pharmacol. 2015;65(6):555–561. DOI: 10.1097/FJC.0000000000000223.Gholamzadeh A., Amini S., Mohammadpour A.H., Vahabzadeh M., Fazelifar A.F., Fazlinezhad A. et al. Erythropoietin reduces PostPCI arrhythmias in patients with ST-elevation myocardial infarction. J. Cardiovasc. Pharmacol. 2015;65(6):555–561. DOI: 10.1097/FJC.0000000000000223.Orii M., Hirata K., Takemoto K., Akasaka T. Effect of erythropoietin administration on myocardial viability and coronary microvascular dysfunction in anterior acute myocardial infarction: Randomized controlled trial in the Japanese Population. Cardiol. Ther. 2018;7(2):151–162. DOI: 10.1007/s40119-018-0122-1.Orii M., Hirata K., Takemoto K., Akasaka T. Effect of erythropoietin administration on myocardial viability and coronary microvascular dysfunction in anterior acute myocardial infarction: Randomized controlled trial in the Japanese Population. Cardiol. Ther. 2018;7(2):151–162. DOI: 10.1007/s40119-018-0122-1.Seo W.-W., Suh J.-W., Oh I.-Y., Yoon C.H., Cho Y.S., Youn T.J. et al. Efficacy of intracoronary erythropoietin delivery before reperfusion-gauging infarct size in patients with acute ST-segment elevation myocardial infarction (ICEBERG). Int. Heart J. 2019;60(2):255–263. DOI: 10.1536/ihj.18-035.Seo W.-W., Suh J.-W., Oh I.-Y., Yoon C.H., Cho Y.S., Youn T.J. et al. Efficacy of intracoronary erythropoietin delivery before reperfusion-gauging infarct size in patients with acute ST-segment elevation myocardial infarction (ICEBERG). Int. Heart J. 2019;60(2):255–263. DOI: 10.1536/ihj.18-035.Minamino T., Higo S., Araki R., Hikoso S., Nakatani D., Suzuki H. et al. EPO-AMI-II investigators. Low-dose erythropoietin in patients with ST-segment elevation myocardial infarction (EPO-AMI-II) – A randomized controlled clinical trial. Circ. J. 2018;82(4):1083–1091. DOI: 10.1253/circj.CJ-17-0889.Minamino T., Higo S., Araki R., Hikoso S., Nakatani D., Suzuki H. et al. EPO-AMI-II investigators. Low-dose erythropoietin in patients with ST-segment elevation myocardial infarction (EPO-AMI-II) – A randomized controlled clinical trial. Circ. J. 2018;82(4):1083–1091. DOI: 10.1253/circj.CJ-17-0889.Маслов Л.Н., Нарыжная Н.В., Цибульников С.Ю., Воронков Н.С., Бушов Ю.В. Роль натрийуретических пептидов и эритропоэтина в регуляции толерантности сердца к действию ишемии и реперфузии. Анализ экспериментальных и клинических данных. Рос. физиол. журн. им. И.М. Сеченова. 2019;105(1):24–35. DOI: 10.1134/S0869813919010060.Maslov L.N., Naryzhnaya N.V., Tsibulnikov S.Yu., Voronkov N.S., Bushov Yu.V. The role of natriuretic peptides and erythropoietin in the regulation of cardiac tolerance to the impact of ischemia and reperfusion. Analysis of experimental and clinical data. Russian Journal of Physiology name by I.M. Sechenov. 2019;105(1):24–35. (In Russ.). DOI: 10.1134/S0869813919010060.

The authors declare that there are no conflicts of interest present.